Last reviewed · How we verify

FF/UMEC/VI (100/62.5/25) mcg — Competitive Intelligence Brief

FF/UMEC/VI (100/62.5/25) mcg (FF/UMEC/VI (100/62.5/25) mcg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triple combination inhaler (ICS/LAMA/LABA). Area: Respiratory/Pulmonology.

phase 3 Triple combination inhaler (ICS/LAMA/LABA) Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

FF/UMEC/VI (100/62.5/25) mcg (FF/UMEC/VI (100/62.5/25) mcg) — GlaxoSmithKline. FF/UMEC/VI is a triple-combination inhaled therapy that combines a long-acting beta-2 agonist, a long-acting muscarinic antagonist, and an inhaled corticosteroid to reduce airway inflammation and improve bronchodilation in chronic obstructive pulmonary disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
FF/UMEC/VI (100/62.5/25) mcg TARGET FF/UMEC/VI (100/62.5/25) mcg GlaxoSmithKline phase 3 Triple combination inhaler (ICS/LAMA/LABA) Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
FF/UMEC/VI FF/UMEC/VI Dr. Grace Parraga marketed Triple combination inhaler (ICS/LAMA/LABA) Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
Triple FF/UMEC/VI Triple FF/UMEC/VI GlaxoSmithKline phase 3 ICS/LAMA/LABA combination Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
CHF 5993 200/6/12.5 µg CHF 5993 200/6/12.5 µg Chiesi Farmaceutici S.p.A. phase 3 Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
GFF MDI GFF MDI Pearl Therapeutics, Inc. phase 3 Combination inhaled corticosteroid / long-acting beta-2 agonist / long-acting muscarinic antagonist Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
BGF MDI (PT010) BGF MDI (PT010) Pearl Therapeutics, Inc. phase 3 Triple-combination inhaler (ICS/LABA/LAMA) Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/31.25/25) mcg GlaxoSmithKline phase 3 Triple combination inhaler (ICS/LAMA/LABA) Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triple combination inhaler (ICS/LAMA/LABA) class)

  1. GlaxoSmithKline · 3 drugs in this class
  2. Dr. Grace Parraga · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FF/UMEC/VI (100/62.5/25) mcg — Competitive Intelligence Brief. https://druglandscape.com/ci/ff-umec-vi-100-62-5-25-mcg. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: